Retrospective comparison of hematopoietic stem cell transplantation following reduced-intensity conditioning with fludarabine/low-dose melphalan plus 4 Gy TBI versus fludarabine/ busulfan plus 4 Gy TBI

Fludarabine with intravenous busulfan (6.4 mg/kg; FB2) and fludarabine with intermediate-dose melphalan (140 mg/m 2 ; FM140) are the most widely used reduced-intensity conditioning (RIC) regimens for allogeneic hematopoietic stem cell transplantation. FM140 generally has a lower relapse rate and hig...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International journal of hematology 2022-02, Vol.115 (2), p.244-254
Hauptverfasser:	Yamada, Yuta, Ikegawa, Shuntaro, Najima, Yuho, Atsuta, Yuya, Konuma, Ryosuke, Adachi, Hiroto, Wada, Atsushi, Kishida, Yuya, Konishi, Tatsuya, Nagata, Akihito, Kaito, Satoshi, Nagata, Ryohei, Noguchi, Yuma, Marumo, Atsushi, Mukae, Junichi, Inamoto, Kyoko, Toya, Takashi, Igarashi, Aiko, Kobayashi, Takeshi, Sakamaki, Hisashi, Ohashi, Kazuteru, Doki, Noriko
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antineoplastic Agents - therapeutic use Busulfan Busulfan - therapeutic use Conditioning Female Fludarabine Graft versus host disease Graft vs Host Disease - etiology Graft vs Host Disease - prevention & control Graft-versus-host reaction Health risks Hematology Hematopoietic Stem Cell Transplantation - methods Hematopoietic stem cells Humans Intravenous administration Irradiation Male Medicine Medicine & Public Health Melphalan Melphalan - therapeutic use Middle Aged Myeloablative Agonists - therapeutic use Oncology Original Article Radiation Retrospective Studies Stem cell transplantation Stem cells Survival Survival Analysis Transplantation Transplantation Conditioning - methods Transplantation, Homologous Vidarabine - analogs & derivatives Vidarabine - therapeutic use Whole-Body Irradiation
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!